Clinical outcome of patients with refractory Kawasaki disease based on treatment modalities

PURPOSE: Although a significant number of reports on new therapeutic options for refractory Kawasaki disease (KD) such as steroid, infliximab, or repeated intravenous immunoglobulin (IVIG) are available, their effectiveness in reducing the prevalence of coronary artery lesions (CAL) remains controve...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyun Jung, Lee, Hyo Eun, Yu, Jae Won, Kil, Hong Ryang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Pediatric Society 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014912/
https://www.ncbi.nlm.nih.gov/pubmed/27610181
http://dx.doi.org/10.3345/kjp.2016.59.8.328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014912/
https://www.ncbi.nlm.nih.gov/pubmed/27610181
http://dx.doi.org/10.3345/kjp.2016.59.8.328

Ejemplares similares